RMD vs TCMD
RMD: ResMed is a leading provider of AI-powered, cloud-connected medical devices and software that revolutionize the management of sleep apnea and chronic respiratory conditions at home. TCMD: A medical technology company providing clinically proven, at-home therapy solutions for lymphedema, chronic venous insufficiency, and respiratory conditions.
Side-by-side fundamentals
| Metric | RMD | TCMD | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $226.73 | $22.12 | |
| Market cap | $32.7B | $501M | |
| P/E as of 2026-10-08 | 21.73 | 25.08 | RMD lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2026 | 1.11 | n/a | |
| Net margin | +26.9% | +5.8% | RMD higher |
| Gross margin | +61.1% | +75.9% | TCMD higher |
| Operating margin | +33.4% | +8.9% | RMD higher |
| ROE | +23.1% | +8.7% | RMD higher |
| ROA | +17.0% | +7.0% | RMD higher |
| Debt / equity as of 2026-09-02 | 0.10 | 0.00 | TCMD lower |
| Revenue growth (YoY) as of 2026-09-02 | +9.8% | +17.2% | TCMD higher |
| Revenue CAGR (3y) SEC XBRL | +10.2% | +10.1% | RMD higher |
| Dividend yield as of 2026-09-02 | +1.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 14 | 0 | RMD higher |
| Beta as of 2026-09-02 | 0.58 | 0.72 | |
| 1-year return as of 2026-10-08 close | -19.7% | +48.5% | TCMD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.